碘复合物治疗轻中度COVID-19的四盲安慰剂对照随机试验方案摘要
该试验为四盲、随机、安慰剂对照的优势性研究,计划纳入200例PCR确诊的轻中度COVID-19成人患者,按1:1:1:1分配至三种碘复合物制剂组或安慰剂组,所有组均接受标准治疗。主要结局为病毒清除及影像学和临床改善,次要结局包括30天死亡率。
要点
- 离子碘聚合物复合物含200mg元素碘,三种剂型每日三次给药。
- 主要结局为病毒清除、影像学及临床改善,随访至12天或症状缓解。
- 四盲设计涵盖受试者、照护者、研究者和结局评估者。
核心结论
- 该方案旨在评估离子碘聚合物复合物对轻中度COVID-19患者临床和影像学改善的疗效。
研究设计与样本
- 封闭标签、随机、安慰剂对照、四盲、优势性框架,1:1:1:1分配。
- 计划从巴基斯坦拉合尔的三个中心纳入200例PCR确诊的轻中度COVID-19成人患者。
- 排除有既往慢性疾病的患者。
关键数值与推荐
- 干预组分别接受胶囊200mg、糖浆40ml或咽喉喷雾2喷的碘复合物,每日三次;对照组接受空胶囊。
- 所有组均接受巴基斯坦国家卫生服务部COVID-19临床管理指南第3.0版的标准治疗。
- 主要结局为病毒清除及影像学和临床改善,SARS-CoV-2 RT-PCR和HRCT chest在入院当天及之后每4天检测一次,持续12天或至症状缓解。
- 次要结局包括症状缓解时间和30天死亡率。
- 采用分层随机(初始COVID-19状态或症状天数、年龄组、性别、基线症状严重程度和合并症)和抽签法。
临床怎么用
- 该试验结果将为碘复合物作为轻中度COVID-19辅助治疗的疗效提供证据。
局限性
- 试验为回顾性注册(NCT04473261,日期2020年7月16日)。
- 样本量200例,可能限制亚组分析效能。
- 排除有既往慢性疾病的患者,结果外推受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The objective of the study is to measure the efficacy of ionic-iodine polymer complex [1] for clinical and radiological improvement in coronavirus disease 2019 (COVID-19) patients. TRIAL DESIGN: The trial will be closed label, randomized and placebo-controlled with a 1:1:1:1 allocation ratio and superiority framework. PARTICIPANTS: All PCR confirmed COVID-19 adult patients including non-pregnant females, with mild to moderate disease, will be enrolled from Shaikh Zayed Post-Graduate Medical Complex, Ali Clinic and Doctors Lounge in Lahore (Pakistan). Patients with any pre-existing chronic illness will be excluded from the study. INTERVENTION AND COMPARATOR: In this multi-armed study ionic-iodine polymer complex with 200 mg of elemental iodine will be given using three formulations to evaluate efficacy. Patients will be receiving either encapsulated iodine complex of 200 mg (arm A), iodine complex syrup form 40 ml (arm B), iodine complex throat spray of 2 puffs (arm C) or empty capsule (arm D) as placebo; all three times a day. All the 4 arms will be receiving standard care as per version 3.0 of the clinical management guidelines for COVID-19 established by the Ministry of National Health Services of Pakistan. MAIN OUTCOMES: Primary outcomes will be viral clearance with radiological and clinical improvement. SARS-CoV-2 RT-PCR and HRCT chest scans will be done on the admission day and then after every fourth day for 12 days or till the symptoms are resolved. RT-PCR will only be shown as positive or negative while HRCT chest scoring will be done depending on the area and severity of lung involvement [2]. Time taken for the alleviation of symptoms will be calculated by the number of days the patient remained symptomatic. 30-day mortality will be considered as a secondary outcome. RANDOMISATION: Stratification for initial COVID-19 status (or days from initial symptoms as a proxy), age groups, gender, baseline severity of symptoms and co-morbidities will be used to ensure that the study arms remain balanced in size for the 1:1:1:1 allocation ratio. Randomization will be done using the lottery method. As patients are being admitted at different times, they will be recruited after obtaining their voluntary written informed consent following all standard protocols of the infection, control and disinfection. BLINDING (MASKING): This is a quadruple (participants, care providers, investigators and outcomes assessors) blinded study where only the study's Primary Investigator will have information about the arms and their interventions. NUMBERS TO BE RANDOMISED (SAMPLE SIZE): 200 patients will be randomized into four groups with three experimental and one placebo arm. TRIAL STATUS: Protocol Version Number is 2.3 and it is approved from IRB Shaikh Zayed Hospital with ID SZMC/IRB/Internal0056/2020 on July 14th, 2020. The recruitment is in progress. It was started on July 30, 2020, and the estimated end date for the trial is August 15, 2021. TRIAL REGISTRATION: Clinical Trial has been retrospectively registered on www.clinicaltrials.gov with registration ID NCT04473261 dated July 16, 2020. FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). With the intention of expediting dissemination of this trial, the conventional formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol. The study protocol has been reported in accordance with the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines.
引用
- Ashraf S, Ashraf S, Ashraf M, et al. A quadruple blinded placebo controlled randomised trial to evaluate the effectiveness of an Iodine complex for patients with mild to moderate COVID-19 in Pakistan (I-COVID-PK): A structured summary of a study protocol for a randomised controlled trial. Trials. 2021. PMID: 33568226. doi:10.1186/s13063-021-05081-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。